305 related articles for article (PubMed ID: 24167028)
1. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.
Hanna-Mitchell AT; Wolf-Johnston AS; Barrick SR; Kanai AJ; Chancellor MB; de Groat WC; Birder LA
Neurourol Urodyn; 2015 Jan; 34(1):79-84. PubMed ID: 24167028
[TBL] [Abstract][Full Text] [Related]
2. Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
Liu HT; Chen SH; Chancellor MB; Kuo HC
PLoS One; 2015; 10(8):e0134803. PubMed ID: 26241848
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
Smith CP; Gangitano DA; Munoz A; Salas NA; Boone TB; Aoki KR; Francis J; Somogyi GT
Neurochem Int; 2008 May; 52(6):1068-75. PubMed ID: 18187233
[TBL] [Abstract][Full Text] [Related]
4. Targets for botulinum toxin in the lower urinary tract.
Cruz F
Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898
[TBL] [Abstract][Full Text] [Related]
5. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A.
Smith CP; Vemulakonda VM; Kiss S; Boone TB; Somogyi GT
Neurochem Int; 2005 Sep; 47(4):291-7. PubMed ID: 15970360
[TBL] [Abstract][Full Text] [Related]
6. Re: Hanna-Mitchell AT, Wolf-Johnston AS, Barrick SR, et al. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn 2015;34:79-84.
Lavelle JP
Neurourol Urodyn; 2015 Jan; 34(1):85. PubMed ID: 24151021
[No Abstract] [Full Text] [Related]
7. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury.
Khera M; Somogyi GT; Kiss S; Boone TB; Smith CP
Neurochem Int; 2004 Dec; 45(7):987-93. PubMed ID: 15337297
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB
Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904
[TBL] [Abstract][Full Text] [Related]
9. BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves.
Ibrahim H; Maignel J; Hornby F; Daly D; Beard M
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051030
[TBL] [Abstract][Full Text] [Related]
10. Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves.
Chuang YC; Huang TL; Tyagi P; Huang CC
J Urol; 2016 Aug; 196(2):599-608. PubMed ID: 26724396
[TBL] [Abstract][Full Text] [Related]
11. Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder.
Beckel JM; Daugherty SL; Tyagi P; Wolf-Johnston AS; Birder LA; Mitchell CH; de Groat WC
J Physiol; 2015 Apr; 593(8):1857-71. PubMed ID: 25630792
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
13. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity.
Ha US; Park EY; Kim JC
Urology; 2011 Sep; 78(3):721.e1-721.e6. PubMed ID: 21782224
[TBL] [Abstract][Full Text] [Related]
14. Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium.
Ochodnický P; Michel MB; Butter JJ; Seth J; Panicker JN; Michel MC
Pharmacol Res; 2013 Apr; 70(1):147-54. PubMed ID: 23376352
[TBL] [Abstract][Full Text] [Related]
15. Mucosal modulation of contractility in bladder strips from normal and overactive rat models and the effect of botulinum toxin A on overactive bladder strips.
Campbell PC; McDonnell B; Monaghan KP; Baysting L; Little O; McCloskey KD
Neurourol Urodyn; 2017 Apr; 36(4):1052-1060. PubMed ID: 27494539
[TBL] [Abstract][Full Text] [Related]
16. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.
Lawrence GW; Aoki KR; Dolly JO
J Pharmacol Exp Ther; 2010 Sep; 334(3):1080-6. PubMed ID: 20576797
[TBL] [Abstract][Full Text] [Related]
17. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.
Dolly JO; Lawrence GW
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137
[TBL] [Abstract][Full Text] [Related]
18. Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release.
Bravo G; Massa H; Rose'Meyer R; Chess-Williams R; McDermott C; Sellers DJ
Naunyn Schmiedebergs Arch Pharmacol; 2017 May; 390(5):547-556. PubMed ID: 28190243
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Lin YH; Chiang BJ; Liao CH
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
[TBL] [Abstract][Full Text] [Related]
20. Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions.
Sui G; Fry CH; Montgomery B; Roberts M; Wu R; Wu C
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F286-98. PubMed ID: 24285497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
